PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-18-0177
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2016English

Inhibition of Mitochondria- And Endoplasmic Reticulum Stress-Mediated Autophagy Augments Temozolomide-Induced Apoptosis in Glioma Cells

PLoS ONE
Multidisciplinary
2012English

Bevacizumab Monotherapy for Temozolomide-Refractory Malignant Glioma

Japanese Journal of Neurosurgery
SurgeryNeurology
2010English

Mismatch Repair Defects andO6-Methylguanine-DNA Methyltransferase Expression in Acquired Resistance to Methylating Agents in Human Cells

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
1997English

MYC Inhibition Plus P53 Stabilization Targets Leukemic Stem Cells

Cancer Discovery
Oncology
2016English

Mismatch Repair Deficiency Is Associated With Resistance to DNA Minor Groove Alkylating Agents

British Journal of Cancer
Cancer ResearchOncology
1999English

MicroRNA-93 Promotes the Malignant Phenotypes of Human Glioma Cells and Induces Their Chemoresistance to Temozolomide

Biology Open
BiochemistryAgriculturalGeneticsMolecular BiologyBiological Sciences
2016English

NCK1-AS1 Increases Drug Resistance of Glioma Cells to Temozolomide by Modulating miR-137/TRIM24

Cancer Biotherapy and Radiopharmaceuticals
Nuclear MedicineRadiologyPharmacologyCancer ResearchOncologyImagingMedicine
2020English

The Strategy for Enhancing Temozolomide Against Malignant Glioma

Frontiers in Oncology
Cancer ResearchOncology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy